Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Junho 2023 - 5:05PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on
transforming medicines to transform lives, today announced that the
Compensation Committee of Avadel’s Board of Directors approved the
grant of non-statutory options to fifteen (15) new employees to
purchase an aggregate of 129,000 ordinary shares under Avadel’s
2021 Inducement Plan. The awards were granted on June 5, 2023, as
an inducement material to the employee’s acceptance of employment
with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The
options have a ten-year term and vest over four years, with 25%
vesting on the one-year anniversary of the grant date and 25% on
each anniversary thereafter. The options are subject to the terms
and conditions of Avadel’s 2021 Inducement Plan approved by the
Board of Directors in November 2021 and the terms and conditions of
award agreements covering the grants.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical
company focused on transforming medicines to transform lives. Our
approach includes applying innovative solutions to the development
of medications that address the challenges patients face with
current treatment options. Avadel's commercial product, LUMRYZ™,
was approved by the U.S. Food & Drug Administration (FDA) as
the first and only once-at-bedtime oxybate for the treatment of
cataplexy or excessive daytime sleepiness (EDS) in adults with
narcolepsy. For more information, please
visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com(212)
698-8687
Media Contact:Gabriella GreigReal
Chemistryggreig@realchemistry.com(203)
249-2688
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024